Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276295 | 0.71 | CYP2A6 (0.55) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL1866237 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL3799554 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL14022908 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL911242 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL2011067 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL389275 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL594318 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL156699 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 | |
| SCHEMBL5869169 | 0.71 | CYP2A6 (0.50) | CYP2A6HDAC4DAOPIM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | claimed |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2017-07-06 | — | — | US | claimed |
| EP-2944633-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2015-11-18 | — | — | EP | claimed |
| EP-2427451-B1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PRISM BIOLAB CO LTD (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | Prism BioLab Co., Ltd. (JP) | 2018-10-25 | — | — | US | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-3339302-A1 | PYRIDINE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-06-27 | — | — | EP | disclosed |
| EP-2944633-B1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9682996-B2 | Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions | Prism BioLab Co., Ltd. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9637469-B2 | Pyridine derivative | TEIJIN PHARMA LIMITED (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-0702013-A2 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1996-03-20 | — | — | EP | disclosed |
| CN-1109057-A | Imidazopyridazine | MERCK PATENT GMBH (DE) | 1995-09-27 | — | — | CN | disclosed |
| US-5438063-A | Hypotensive agents, cardiac insufficiency, increased intraocular pressure, and CNS disorders | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0657454-A1 | Imidazopyridazines being angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1995-06-14 | — | — | EP | disclosed |
| US-5389642-A | Exhibit antagonistic properties toward angiotensin(II); useful for treatment of hypertensioni, aldosteronism, cardiac insufficiency, increased intraocular pressure and disorders of the central nervous system | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-14 | — | — | US | disclosed |
| EP-0628556-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| CN-1094044-A | Imidazopyridine | MERCK PATENT GMBH (DE) | 1994-10-26 | — | — | CN | disclosed |
| EP-0602521-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0547514-A2 | Imidazopyridine derivatives with angiotensin-II antagonist properties | MERCK PATENT GmbH (DE) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305373-A1 | ALPHA HELIX MIMETICS AND METHODS RELATING THERETO | PLOD3, COL1A1, THPO | CYP2A6 2913/4885HDAC4 1750/4885DAO 463/4885 |
| US-20170190694-A1 | PYRIDINE DERIVATIVE | HPRT1, XDH, NUDT1 | CYP2A6 1634/4885HDAC4 2744/4885DAO 1854/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | CYP2A6 2913/4885HDAC4 1750/4885DAO 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.